Overview
Inflammation inhibitors are a class of drugs that have gained significant attention in the field of medical research. These inhibitors are designed to suppress the immune system's response to damage, thus reducing inflammation. The use of inflammation inhibitors has been demonstrated to alleviate many symptoms associated with the coronavirus, as COVID-19 is known to induce a high level of inflammation in its victims. The virus triggers an immune response in the host that causes an overreaction of the immune system over a prolonged period, causing severe inflammation. The resulting inflammation can cause many of the symptoms that are associated with COVID-19, including cough, fatigue, and fever. The most popular class of inflammation inhibitors is nonsteroidal anti-inflammatory drugs (NSAIDs), which suppress the production of prostaglandins. Other inflammation inhibitors include corticosteroids, which inhibit the transcription of various cytokines and interleukins, and monoclonal antibodies that target pro-inflammatory cytokines like IL-6. Studies have shown that the use of inflammation inhibitors like NSAIDs in combination with other treatments is an effective way to combat the effects of COVID-19. Researchers are continuing to investigate the efficiency and safety of these treatments to develop more effective and targeted treatments for the virus. Overall, while inflammation inhibitors show great promise in managing many of the symptoms of COVID-19, more research is needed to establish their efficacy and safety in treating the virus. The development of more refined and targeted drugs will likely be an essential part of the effort to combat the pandemic, and investigators will continue their search to create new treatments for COVID-19.
Research published in this journal
3 peer-reviewed articles, ranked by relevance. Each links to its DOI.
COVID-19 Pandemic: The Causative Agent is New, The Problem is Old
How this research is being cited
The 3 articles above have been cited 3 times in the scholarly literature. Citation data via OpenAlex and Crossref, updated Jun 2026.
-
2021 · Open Access Journal of Pulmonary & Respiratory Sciences
-
2020 · Jurnal Ilmu Administrasi Media Pengembangan Ilmu dan Praktek Administrasi
-
2020 · Jurnal Ilmu Administrasi: Media Pengembangan Ilmu dan Praktek Administrasi
A sample of recent works citing this journal's research on Inflammation Inhibitors, linking to each citing work.